Introduction
Revlixen 25 mg (Lenalidomide) Capsule is a powerful immunomodulatory agent used in the treatment of various hematologic malignancies. Manufactured by Everest Pharmaceuticals Ltd., a trusted name in oncology formulations, and supplied globally by Onco Solution, Revlixen plays a vital role in modern cancer care. It is indicated for patients with multiple myeloma (MM), myelodysplastic syndromes (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).
Key Benefits
- Inhibits tumor cell proliferation
- Boosts immune response against cancer
- Reduces abnormal blood cell production in MDS
- Synergistic activity with Dexamethasone in MM
- Supports maintenance therapy post-stem cell transplant
Indications
Revlixen is approved for:
- Multiple Myeloma: Combination with Dexamethasone; maintenance post-autologous HSCT
- Myelodysplastic Syndromes: With deletion 5q cytogenetic abnormality
- Mantle Cell Lymphoma: Relapsed/progressed after 2 prior therapies including Bortezomib
- Follicular & Marginal Zone Lymphomas: In combination with Rituximab
Note: Not recommended for CLL outside clinical trials.
Dosage & Administration
For Multiple Myeloma:
- Induction (Combo with Dexamethasone): 25 mg/day on Days 1-21 of 28-day cycle
- Maintenance (Post-HSCT): 10 mg/day continuously; increase to 15 mg after 3 cycles if tolerated
For MDS:
- 10 mg daily, continued until progression or toxicity
For MCL:
- 25 mg/day on Days 1-21 of 28-day cycle
For FL or MZL:
- 20 mg/day on Days 1-21 of 28-day cycle for up to 12 cycles (with Rituximab)
Administration Advice:
- Take at the same time daily
- With or without food
- Swallow whole with water; do not crush or chew
Pharmacology
Lenalidomide works by binding cereblon, leading to degradation of Ikaros, Aiolos, and CK1α proteins. This results in:
- Tumor cell apoptosis
- Inhibition of pro-inflammatory cytokines (e.g., IL-6, TNF-α)
- Enhanced immune response through T and NK cell activation
Pharmacokinetics:
- Rapid absorption (Cmax 0.5–6 hrs post-dose)
- 30% plasma protein binding
- Renal elimination (82% unchanged in urine)
- Half-life: 3–5 hours
Drug Interactions
- Digoxin: Monitor levels due to 14% increase in AUC
- Warfarin: Monitor PT/INR when used concurrently
- Estrogens/ESAs: Caution due to thrombosis risk
Contraindications
- Pregnancy (teratogenic)
- Severe hypersensitivity (e.g., SJS, TEN, angioedema)
Side Effects
Common:
- Neutropenia, thrombocytopenia
- Fatigue, diarrhea, constipation
- Rash, back pain
Serious:
- Embryo-fetal toxicity
- Hepatotoxicity
- Second primary malignancies
- Severe cutaneous reactions
- Thromboembolic events
Warnings & Precautions
- REMS Program: Revlixen available only under controlled distribution
- Hematologic Monitoring: Weekly for first cycles, then monthly
- Hepatotoxicity: Monitor ALT/AST, bilirubin
- TLS/TFR: Watch for tumor flare reactions
- Stem Cell Mobilization: Plan early in MM treatment
- Thyroid Function: Monitor TSH regularly
Use in Special Populations
- Pediatrics: Safety not established
- Pregnancy & Lactation: Contraindicated
- Geriatrics: Dose adjustments may be necessary
Storage & Handling
Store below 30°C, protect from light and moisture. Keep out of children’s reach.
Manufacturer Information
Everest Pharmaceuticals Ltd. is a WHO-GMP-certified Bangladeshi company, known for its excellence in high-quality oncology medicines across the globe.
Supplier Profile: Onco Solution
Onco Solution is a global supplier of oncology medications, committed to bridging gaps in cancer care worldwide. With streamlined logistics and regulatory expertise, we ensure timely delivery of products like Revlixen 25 mg to hospitals, clinics, and healthcare providers.
Conclusion
Revlixen 25 mg (Lenalidomide) Capsule by Everest Pharmaceuticals Ltd., supplied by Onco Solution, is a cornerstone in hematologic cancer management. From multiple myeloma to lymphomas, it offers multi-pathway efficacy and immunomodulatory benefits. Trust Onco Solution for consistent global access and expert support in oncology therapy.
